Sui Yun-Peng, Jian Xue-Ping, Ma L I, Xu Gui-Zhen, Liao Huai-Wei, Liu Yan-Ping, Wen Hui-Cai
Department of Plastic Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
Mol Clin Oncol. 2016 Jan;4(1):77-82. doi: 10.3892/mco.2015.651. Epub 2015 Oct 7.
CD133 has been identified as a putative neoplastic stem cell marker in esophageal carcinoma. However, the prognostic value of CD133 overexpression in patients with esophageal carcinoma remains controversial. A meta-analysis of previous studies was performed, in order to assess the association of CD133 overexpression with the clinicopathological characteristics of esophageal carcinoma patients. A total of 7 studies, including 538 patients, were subjected to the final analysis. Our results indicated that a positive CD133 expression was significantly associated with lymph node metastasis [odds ratio (OR)=3.09, 95% confidence interval (CI): 1.93-4.95; P<0.00001], clinical stage (OR=4.26, 95% CI: 1.55-11.73; P=0.005) and histopathological grade (OR=2.40, 95% CI: 1.16-4.94; P=0.02). There was no statistically significant association of CD133 with depth of invasion (OR=1.89, 95% CI: 0.42-8.43; P=0.41). Based on the results of this study, we concluded that CD133 is an efficient prognostic factor in esophageal carcinoma. Higher CD133 expression is significantly associated with lymph node metastasis, clinical stage and histopathological grade.
CD133已被确定为食管癌中一种假定的肿瘤干细胞标志物。然而，CD133过表达在食管癌患者中的预后价值仍存在争议。为了评估CD133过表达与食管癌患者临床病理特征之间的关联，对先前的研究进行了荟萃分析。共有7项研究（包括538例患者）纳入最终分析。我们的结果表明，CD133阳性表达与淋巴结转移显著相关[比值比（OR）=3.09，95%置信区间（CI）：1.93 - 4.95；P<0.00001]、临床分期（OR = 4.26，95% CI：1.55 - 11.73；P = 0.005）和组织病理学分级（OR = 2.40，95% CI：1.16 - 4.94；P = 0.02）。CD133与浸润深度之间无统计学显著关联（OR = 1.89，95% CI：0.42 - 8.43；P = 0.41）。基于本研究结果，我们得出结论，CD133是食管癌的一个有效预后因素。CD133表达升高与淋巴结转移、临床分期和组织病理学分级显著相关。
